Object Details
- Genentech, Inc.
- Description (Brief)
- (From insert) Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In patients with an FVC of greater than or equal to 40% of predicited, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requireing parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.
- Location
- Currently not on view
- Credit Line
- Gift of Genentech, Inc.
- ca 2013
- product expiration date
- 2014-08
- ID Number
- 2013.0069.03
- catalog number
- 2013.0069.03
- accession number
- 2013.0069
- Object Name
- pharmaceutical
- biological
- Physical Description
- plastic (overall material)
- cardboard (overall material)
- dornase alfa, 2.5 mg per ampule (overall ingredient)
- Measurements
- overall: 4 1/2 in x 4 3/4 in x 2 1/2 in; 11.43 cm x 12.065 cm x 6.35 cm
- foil packet: 1/2 in x 4 1/4 in; 1.27 cm x 10.795 cm
- overall: 4 1/2 in x 4 3/4 in x 2 5/8 in; 11.43 cm x 12.065 cm x 6.6675 cm
- place made
- United States: California, South San Francisco
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- National Museum of American History
- Record ID
- nmah_1445141
- GUID (Link to Original Record)
- https://n2t.net/ark:/65665/ng49ca746ad-d912-704b-e053-15f76fa0b4fa
